Date: 2013-10-10
Type of information:
phase:
Announcement: results
Company: S-TARget therapeutics (Austria)
Product: SG100
Action mechanism:
Disease: allergic asthma caused by house dust mite (HDM) allergens
Therapeutic area: Allergic diseases - Inflammatory diseases - Respiratory diseases
Country:
Trial details:
Latest
news: * On October 10, 2013, S-TARget therapeutics, a biotechnology company developing vaccines that address the cause of severe allergic diseases, has announced that it has achieved clinical proof of concept for its drug candidate SG100 in non-human primates. SG100 is being developed for the prevention and therapy of severe allergic asthma caused by house dust mite (HDM) allergens. In this study, where SG100 was applied to cynomolgus monkeys suffering from house dust mite induced severe chronic allergic asthma, S-TARget has demonstrated that repeated injections of SG100 were able to significantly improve clinical symptoms of both the early as well as the late asthmatic reactions. The placebo control group did not improve. Changes were observed even 90 days after treatment indicating that SG100 has successfully reprogrammed the immune system. The study has also shown that SG100 can be safely applied in highly allergic individuals; only minor local side effects were observed.“Having generated this highly promising data in a clinically predictive proof-of-concept study is ‘the’ pivotal achievement so far for S-TARget’s technology and the entire company”, commented Christof Langer, MBA, Chief Executive Officer and Co-founder of S-TARget. “This set of data provides extraordinary assurance for further investments in S-TARget. Based on the results of this study we are in good shape to raise the funds to move SG100 into clinical development and initiate a Phase I/II clinical trial in 2015.”
